title: Chronic kidney disease anemia management: what should be done?
abstract: A transition in the approach to anemia management in nephrology occurred when randomized trials demonstrated that higher hemoglobin targets do not result in better outcomes and may arguably cause harm. Contradicting the speculative conclusions drawn based on earlier observational data, this has resulted in hypotheses regarding the cause of these seemingly disparate but substantively similar messages. The renal community now must struggle with how to incentivize quality care and maximize patient quality of life while minimizing the real safety signal of which we are now aware.
authors.affiliation: Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA. szcze001@mc.duke.edu
authors.forename: Lynda Anne
authors.initials: LA
authors.lastname: Szczech
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology*; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D051436:Renal Insufficiency, Chronic / Q000150:complications*
chemical_list: D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa